Following a limited submission
AWMSG advice |
|||
| Status: Recommended | |||
Saxagliptin (Onglyza®) is recommended as an option for use within NHS Wales for the treatment of adult patients aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control in combination with insulin (with or without metformin) when this regimen alone with diet and exercise does not provide adequate glycaemic control. |
|||
|
|||
Medicine details |
|||
| Medicine name | saxagliptin (Onglyza®) | ||
| Formulation | film-coated tablet | ||
| Reference number | 1237 | ||
| Indication | Treatment of adult patients aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control in combination with insulin (with or without metformin) when this regimen alone with diet and exercise does not provide adequate glycaemic control |
||
| Company | AstraZeneca UK Ltd | ||
| BNF chapter | Endocrine system | ||
| Submission type | Limited | ||
| Status | Recommended | ||
| Advice number | 2012 | ||
| NMG meeting date | 12/06/2012 | ||
| AWMSG meeting date | 18/07/2012 | ||
| Ratification by Welsh Government | 07/08/2012 | ||
| Date of issue | 13/08/2012 | ||
| Date of last review | 30/09/2016 | ||